Theravance trumpets positive results of mid-stage trial

Theravance says that its experimental therapy for chronic constipation met its endpoints for all three doses tested in a mid-stage, 400-patient trial. A total of 61 percent of the patients taking the 50 mg dose of TD-5108 responded with increased spontaneous bowel movements as did 60 percent of the patients take a 15 mg dose and 42 percent taking a 30 mg dose. In the placebo arm, 22 percent of patients responded. No serious adverse effects were recorded and headache, diarrhea, nausea and vomiting were listed as the most common side effects. GlaxoSmithKline has a license option for the therapy that dates back to 2004.

- see the release
- read the AP report on the data 

Related Articles:
Theravance declares success in antibiotic trial. Report
Theravance, Astellas ink $65M deal. Report